Overview

Study To Estimate The Relative Bioavailability of Ertugliflozin (PF-04971729, MK-8835) in Healthy Adult Participants (MK-8835-039)

Status:
Completed

Trial end date:
2010-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to examine the rate and extent of absorption of three oral formulations of ertugliflozin (PF 04971729, MK-8835) administered in lean to obese healthy volunteers.

Phase:

Phase 1

Details

Lead Sponsor:

Merck Sharp & Dohme Corp.

Collaborator:

Pfizer

Treatments:

Ertugliflozin